Identification of vasopressor phospholipid in crude soybean lecithin

Abstract

The vasopressor phospholipid in crude soybean lecithin was isolated by column chromatography on Sephadex LH-20. It represented 0.1% of crude soybean lecithin. The isolated phospholipid was identified to be lysophosphatidic acid by gas chromatography-mass spectrometry analysis of TMS-deacylated product and acetolysis product. Nuclear magnetic resonance analysis favored the 1-monoacyl isomer over the 2-isomer. By enzymic determination with L-3-glycerophosphate dehydrogenase, the isolated phospholipid was identified as 1-monoacyl-L-3-glycerophosphate. Gas chromatographic examination revealed that it was composed of a large percentage of unsaturated fatty acids, especially linoleic acid. The activity of isolated lysophosphatidic acid was slightly less than that of synthetic 1-linoleoyl-L-3-glycerophosphate.

Action of Depressor-I, a hypotensive phospholipid from bovine brain, on systemic and arterial blood pressures of various species.

“…The potent cardio vascular activity of lysophosphatidic acid has been described in our own papers (11,21,22).…”

Plant Lysophosphatidic Acids: A Rich Source for Bioactive Lysophosphatidic Acids and Their Pharmacological Applications

“…It was reported that unknown components of soybean lecithin regulate vasoactivity. 4) Further studies revealed that the active ingredients in lecithin were LPAs. LPAs showed differential regulation of vasoactivity, which is dependent on animal species.…”

“…Tokumura et al 4) first reported a novel component in a soybean lecithin fraction showing vasopressor activity in rats. 4) In further studies, they determined that the unknown active ingredient in lecithin was LPA.…”

“…4) In further studies, they determined that the unknown active ingredient in lecithin was LPA. LPA comprises about 0.1% of crude soybean lecithin and this was the first demonstration that plants also contain bioactive LPAs.…”

L’acide lysophosphatidique : un phospholipide « bioactif »

“…La première démonstration de l'existence d'un LPA bioactif remonte à 1963 où W. Vogt démontra que le LPA était impliqué dans l'effet vasoconstricteur induit par des extraits d'intestin de grenouille sur des cellules musculaires lisses de lapin [1]. Plusieurs années après, en 1978, il fut montré que l'injection intraveineuse de LPA conduisait à des effets rapides sur la pression artérielle [2]. À la même période, le LPA, connu comme un puissant facteur pro-agrégant [3], était mis en évidence dans le sang lors de l'agrégation plaquettaire [4].…”